Monaco di Baviera + Düsseldorf + 49.211.5406.5500

Gerd Jaekel is a leading technology and patent lawyer as recognized by clients, the legal press, and the peer group of intellectual property lawyers who practice patent litigation in Europe. His extensive experience in enforcing and defending patents helps clients to successfully navigate global battles they may face. With his broad scientific background as a physicist, he and his team have defended patents in complex intellectual property matters in a wide range of industries, with special focus on consumer electronics, mobile communications, medical devices and biotech, automotive, and aviation. In addition to advising on forensic matters and numerous M&A transactions, Gerd has extensive experience in IP financing transactions and has provided counseling on IP portfolio and risk management.

His IP strategies have been tested in litigation and corporate transactions. Technologies for which Gerd has provided advice and counseling with litigation, prosecution, interferences, oppositions, or invalidation actions include acellular vaccines, aircraft cabin electronics, aluminum rolling, blood centrifuges, business procurements software, capacitors, copy protection systems, credit card systems, data encryption, dental lasers, foils, glass inspection systems, hepatitis delta antibodies, industrial electrolysis, laminate flooring, LEDs, mobile phone circuit testing, non-wovens, online printing, optical devices, orthodontic devices, photoablative lasers, projection devices, robotic systems, scales, semiconductor wafers, spark plugs, and video encryption.

His professional memberships include the German Association for the Protection of Intellectual Property (GRUR), Licensing Executives Society (LES), International Association for the Protection of Intellectual Property (AIPPI), and the German Association of Intellectual Property Experts (VPP). Gerd has participated in multinational symposia and lecturing projects on patent law. He is a frequent speaker on IP and competition law issues.


  • SOLiD defeats patent infringement claims in U.S., UK, and Germany over DAS equipment for 5G technologyJones Day successfully represented SOLiD, Inc. in multi-jurisdictional patent litigation proceedings brought by a competitor who alleged that client's leading Distributed Antenna System ("DAS") solutions infringe claims of six patents (two European and four U.S.).
  • GeneoDx invests in PathoFinderJones Day represented Shanghai GeneoDx Biotech Company Limited, a subsidiary of Sinopharm Group, a leading pharmaceutical company in China, in connection with its investment in PathoFinder Holding B.V. (PFH), which is engaging in molecular diagnostics for the detection of pathogens causing an infectious disease in the Netherlands, by way of purchasing a majority stake in PFH.
  • SAP files DJ action in patent infringement dispute with Wellogix over computer softwareOn behalf of SAP America ("SAP"), Jones Day filed a patent infringement declaratory judgment action involving computer software, which is currently stayed in full pending the conclusion of reexamination proceedings filed by SAP in the USPTO involving the six patents-in-suit.
  • Bio-Rad enforces patent directed to fluorescence detection apparatuses against Thermo Fisher ScientificJones Day represented Bio-Rad Laboratories, Inc., a major life sciences and clinical diagnostics manufacturer, in successfully resolving parallel U.S. and European patent infringement actions, and related inter partes reviews in the U.S. Patent and Trademark Office, against Thermo Fisher Scientific, Inc., in enforcing Bio-Rad's patents relating to fluorescence detection apparatuses useful in polymerase chain reaction (PCR).
  • Materion acquires Heraeus' target materials businessJones Day advised Materion Corporation, a global supplier of highly engineered advanced enabling materials, in its $30 million acquisition of the principal portion of the high-performance target materials business of the Heraeus Group.
  • Celgene appeals decision from Opposition Division to revoke lenalidimide European patentJones Day represents Celgene Corporation in the appeal of a decision in opposition proceedings against two generic companies opposing a Celgene European patent covering the polymorphs of lenalidimide.
  • U.S.-based global supplier of metal semifinished products seeks counseling regarding trade secret misappropriationJones Day advises a U.S.-based global supplier of metal semifinished products on a case of potential trade secret misappropriation.
  • OM Group acquires leading magnetic materials producer Vacuumschmelze for $1 billionJones Day advised OM Group, Inc. (NYSE: OMG) in its acquisition of VAC Vacuumschmelze GmbH & Co KG (VAC) from One Equity Partners, a private equity arm of JPMorgan Chase & Co.
    • February 25, 2017
      The Unitary Patent and the Unified Patent Court
    • November 3, 2014
      IP Box Meets EU Patents
    • 2012年8月15日 (新竹場) 及2012年8月17日 (台北場)